NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $1.69 +0.16 (+10.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.66 -0.03 (-2.07%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pulmonx Stock (NASDAQ:LUNG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pulmonx alerts:Sign Up Key Stats Today's Range$1.53▼$1.7450-Day Range$1.51▼$3.7852-Week Range$1.47▼$9.37Volume1.08 million shsAverage Volume1.03 million shsMarket Capitalization$68.86 millionP/E RatioN/ADividend YieldN/APrice Target$7.66Consensus RatingModerate Buy Company Overview Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Read More Pulmonx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreLUNG MarketRank™: Pulmonx scored higher than 79% of companies evaluated by MarketBeat, and ranked 229th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoveragePulmonx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pulmonx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.55) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.61% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.61% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently decreased by 4.86%, indicating that investor sentiment is improving. News and Social Media1.1 / 5News SentimentN/A Search Interest11 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.MarketBeat Follows3 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold 90.64% more of their company's stock than they have bought. Specifically, they have bought $71,362.00 in company stock and sold $136,044.00 in company stock.Percentage Held by InsidersOnly 6.80% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address LUNG Stock News HeadlinesApreo raises $130M for pivotal trial of emphysema deviceAugust 11, 2025 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live. | The Oxford Club (Ad)Piper Sandler Downgrades Pulmonx (LUNG)July 31, 2025 | msn.com7LUNG : Analyst Expectations For Pulmonx's FutureJuly 31, 2025 | benzinga.comPulmonx slumps as Piper Sandler downgrades despite Q2 beatJuly 31, 2025 | msn.comPulmonx Corporation (LUNG) Q2 2025 Earnings Call TranscriptJuly 30, 2025 | seekingalpha.comPulmonx Reports Second Quarter 2025 Financial ResultsJuly 30, 2025 | globenewswire.comSee More Headlines LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $6.79 at the beginning of the year. Since then, LUNG shares have decreased by 75.1% and is now trading at $1.69. How were Pulmonx's earnings last quarter? Pulmonx Corporation (NASDAQ:LUNG) released its earnings results on Wednesday, July, 30th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. The company had revenue of $23.86 million for the quarter, compared to analysts' expectations of $23.46 million. Pulmonx had a negative net margin of 62.88% and a negative trailing twelve-month return on equity of 69.76%. Read the conference call transcript. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Top institutional investors of Pulmonx include Primecap Management Co. CA (12.67%), JPMorgan Chase & Co. (1.45%), Bank of America Corp DE (1.18%) and Connor Clark & Lunn Investment Management Ltd. (0.54%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, Mehul Joshi, Daniel P Florin, Richard Ferrari, John Mckune and Alissa Hsu Lynch. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pulmonx own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmonx investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings7/30/2025Today8/22/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUNG CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Price Target for Pulmonx$7.66 High Price Target$16.00 Low Price Target$2.50 Potential Upside/Downside+353.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.39 million Net Margins-62.88% Pretax Margin-62.28% Return on Equity-69.76% Return on Assets-36.26% Debt Debt-to-Equity Ratio0.54 Current Ratio5.35 Quick Ratio4.63 Sales & Book Value Annual Sales$83.79 million Price / Sales0.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.70 per share Price / Book0.99Miscellaneous Outstanding Shares40,750,000Free Float37,976,000Market Cap$68.87 million OptionableOptionable Beta0.43 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:LUNG) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.